The emerging role of lncRNAs in inflammatory bowel disease

被引:119
|
作者
Yarani, Reza [1 ]
Mirza, Aashiq H. [2 ]
Kaur, Simranjeet [1 ]
Pociot, Flemming [1 ,3 ,4 ]
机构
[1] Steno Diabet Ctr Copenhagen, Dept Clin Res, Type Diabet Biol 1, Copenhagen, Denmark
[2] Cornell Univ, Weill Cornell Med, Dept Pharmacol, New York, NY 10065 USA
[3] Herlev Univ Hosp, Copenhagen Diabet Res Ctr, Dept Pediat, Herlev, Denmark
[4] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
来源
关键词
LONG NONCODING RNA; ULCERATIVE-COLITIS; GENE-EXPRESSION; GROWTH-ARREST; TRANSCRIPTOME ANALYSIS; BARRIER FUNCTION; TUMOR-GROWTH; T-CELLS; CANCER; UCA1;
D O I
10.1038/s12276-018-0188-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dysregulation of long noncoding RNA (lncRNA) expression is linked to the development of various diseases. Recently, an emerging body of evidence has indicated that lncRNAs play important roles in the pathogenesis of inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative Colitis (UC). In IBD, lncRNAs have been shown to be involved in diverse processes, including the regulation of intestinal epithelial cell apoptosis, association with lipid metabolism, and cell-cell interactions, thereby enhancing inflammation and the functional regulation of regulatory T cells. In this review, we aim to summarize the current knowledge regarding the role of lncRNAs in IBD and highlight potential avenues for future investigation. We also collate potentially immune-relevant, IBD-associated lncRNAs identified through a built-by association analysis with respect to their neighboring protein-coding genes within IBD-susceptible loci. We further underscore their importance by highlighting their enrichment for various aspects of immune system regulation, including antigen processing/presentation, immune cell proliferation and differentiation, and chronic inflammatory responses. Finally, we summarize the potential of lncRNAs as diagnostic biomarkers in IBD.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 50 条
  • [21] Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
    Matthew D McCormack
    Natasha A Wahedna
    David Aldulaimi
    Peter Hawker
    World Journal of Clinical Cases, 2023, (12) : 2621 - 2630
  • [22] Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
    Hala Najeeb
    Farah Yasmin
    Salim Surani
    World Journal of Clinical Cases, 2022, (14) : 4327 - 4333
  • [23] Emerging Role of Dendritic Cell Intervention in the Treatment of Inflammatory Bowel Disease
    Sun, Donglei
    Li, Chenyang
    Chen, Shuang
    Zhang, Xiaolan
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [24] The emerging role of the gut microbiota and its application in inflammatory bowel disease
    Wang, Xiu
    Peng, Jianhua
    Cai, Peipei
    Xia, Yuxuan
    Yi, Chengxue
    Shang, Anquan
    Akanyibah, Francis Atim
    Mao, Fei
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 179
  • [25] Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
    Najeeb, Hala
    Yasmin, Farah
    Surani, Salim
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (14) : 4327 - 4333
  • [26] Emerging treatments for inflammatory bowel disease
    Hazel, Karl
    O'Connor, Anthony
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2020, 11
  • [27] Emerging Therapies for Inflammatory Bowel Disease
    Roni Weisshof
    Katia El Jurdi
    Nada Zmeter
    David T. Rubin
    Advances in Therapy, 2018, 35 : 1746 - 1762
  • [28] Emerging Therapies for Inflammatory Bowel Disease
    Weisshof, Roni
    El Jurdi, Katia
    Zmeter, Nada
    Rubin, David T.
    ADVANCES IN THERAPY, 2018, 35 (11) : 1746 - 1762
  • [29] Emerging biologics in inflammatory bowel disease
    Chan, Heyson Chi-hey
    Ng, Siew Chien
    JOURNAL OF GASTROENTEROLOGY, 2017, 52 (02) : 141 - 150
  • [30] Emerging biologics in inflammatory bowel disease
    Heyson Chi-hey Chan
    Siew Chien Ng
    Journal of Gastroenterology, 2017, 52 : 141 - 150